TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy
Brain · 13.02.2023 · 146 (2) · 475-491
DOI: 10.1093/brain/awac273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 24.07.2022. Verfasst von Aida Marcotti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 San Juan de Alicante, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Transient Receptor Potential Channels, Neuralgia. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Generalitat Valenciana predoctoral fellowship, Spanish Ministry of Education fellowships, ESTEVE Pharmaceuticals S.A..
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy is a frequent, disabling side effect of anticancer drugs. Oxaliplatin, a platinum compound used in the treatment of advanced colorectal cancer, often leads to a form of chemotherapy-induced peripheral neuropathy characterized by mechanical and cold hypersensitivity. Current therapies for chemotherapy-induced peripheral neuropathy are ineffective, often leading to the cessation of treatment. Transient receptor potential ankyrin 1 (TRPA1) is a polymodal, non-selective cation-permeable channel expressed in nociceptors, activated by physical stimuli and cellular stress products. TRPA1 has been linked to the establishment of chemotherapy-induced peripheral neuropathy and other painful neuropathic conditions. Sigma-1 receptor is an endoplasmic reticulum chaperone known to modulate the function of many ion channels and receptors. Sigma-1 receptor antagonist, a highly selective antagonist of Sigma-1 receptor, has shown effectiveness in a phase II clinical trial for oxaliplatin chemotherapy-induced peripheral neuropathy. However, the mechanisms involved in the beneficial effects of Sigma-1 receptor antagonist are little understood. We combined biochemical and biophysical (i.e. intermolecular Förster resonance energy transfer) techniques to demonstrate the interaction between Sigma-1 receptor and human TRPA1. Pharmacological antagonism of Sigma-1R impaired the formation of this molecular complex and the trafficking of functional TRPA1 to the plasma membrane. Using patch-clamp electrophysiological recordings we found that antagonists of Sigma-1 receptor, including Sigma-1 receptor antagonist, exert a marked inhibition on plasma membrane expression and function of human TRPA1 channels. In TRPA1-expressing mouse sensory neurons, Sigma-1 receptor antagonists reduced inward currents and the firing of actions potentials in response to TRPA1 agonists. Finally, in a mouse experimental model of oxaliplatin neuropathy, systemic treatment with a Sigma-1 receptor antagonists prevented the development of painful symptoms by a mechanism involving TRPA1. In summary, the modulation of TRPA1 channels by Sigma-1 receptor antagonists suggests a new strategy for the prevention and treatment of chemotherapy-induced peripheral neuropathy and could inform the development of novel therapeutics for neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 San Juan de Alicante, Spain.
- WeLab Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Spain.
- Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain.
ORCID-Profile: Félix Viana
Förderung
- Generalitat Valenciana predoctoral fellowship
- Spanish Ministry of Education fellowships
- ESTEVE Pharmaceuticals S.A.
- Spanish Ministry of Science and Innovation
- Generalitat Valenciana
Zitieren
APA
Marcotti, A., Fernández-Trillo, J., González, A., Vizcaíno-Escoto, M., Ros-Arlanzón, P., Romero, L., Vela, J. M., Gomis, A., Viana, F., & de la Peña, E. (2023). TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy. Brain, 146(2), 475-491. https://doi.org/10.1093/brain/awac273
Vancouver
Marcotti A, Fernández-Trillo J, González A, Vizcaíno-Escoto M, Ros-Arlanzón P, Romero L, et al. TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy. Brain. 2023;146(2):475-491. doi:10.1093/brain/awac273
BibTeX
@article{Marcotti2023,
author = {Marcotti, Aida and Fernández-Trillo, Jorge and González, Alejandro and Vizcaíno-Escoto, Marta and Ros-Arlanzón, Pablo and Romero, Luz and Vela, José Miguel and Gomis, Ana and Viana, Félix and de la Peña, Elvira},
title = {TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy},
journal = {Brain},
year = {2023},
volume = {146},
number = {2},
pages = {475--491},
doi = {10.1093/brain/awac273}
}
EUVIMED